Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlotte Beaudart

Showing results (1-10 of 193) with videos related to

Pageof 20
Sort By:
The Lancet. Healthy Longevity|February 4, 2024
The influence of physical activity on sarcopeniaCharlotte Beaudart
Climacteric : the Journal of the International Menopause Society|July 9, 2024
Fezolinetant for VMS: a balanced view on efficacy and safety neededJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
Lancet (London, England)|May 18, 2024
Totality of evidence refutes neoplasm risk with fezolinetant - Authors' replyJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
Maturitas|June 10, 2022
Lifestyle approaches to prevent and retard sarcopenia: A narrative reviewOlivier Bruyère, Jean-Yves Reginster, Charlotte Beaudart
Expert Opinion on Pharmacotherapy|September 26, 2024
Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balanceJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
Lancet (London, England)|October 21, 2023
Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetantJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
Menopause (New York, N.Y.)|July 26, 2024
Letter to the EditorJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|June 17, 2024
Letter to the Editor: Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trialsJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
The Patient|February 10, 2026
Patient Preferences Regarding Menopausal Symptoms and Treatments: A Systematic Review of Quantitative Stated-Preference StudiesLucie Raskin, Emma Boretti, Jonathan Douxfils, et al.
BMC Cancer|December 20, 2024
Dose-volume predictors of cardiac adverse events after high-dose thoracic radiation therapy for lung cancer: a systematic review and meta-analysisMédéa Locquet, Sophie Jacob, Xavier Geets, et al.
Pageof 20

Showing results (1-10 of 193) with videos related to

Sort By:
Pageof 20
The Lancet. Healthy Longevity|February 4, 2024
The influence of physical activity on sarcopeniaCharlotte Beaudart
Climacteric : the Journal of the International Menopause Society|July 9, 2024
Fezolinetant for VMS: a balanced view on efficacy and safety neededJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
Lancet (London, England)|May 18, 2024
Totality of evidence refutes neoplasm risk with fezolinetant - Authors' replyJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
Maturitas|June 10, 2022
Lifestyle approaches to prevent and retard sarcopenia: A narrative reviewOlivier Bruyère, Jean-Yves Reginster, Charlotte Beaudart
Expert Opinion on Pharmacotherapy|September 26, 2024
Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balanceJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
Lancet (London, England)|October 21, 2023
Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetantJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
Menopause (New York, N.Y.)|July 26, 2024
Letter to the EditorJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|June 17, 2024
Letter to the Editor: Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trialsJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
The Patient|February 10, 2026
Patient Preferences Regarding Menopausal Symptoms and Treatments: A Systematic Review of Quantitative Stated-Preference StudiesLucie Raskin, Emma Boretti, Jonathan Douxfils, et al.
BMC Cancer|December 20, 2024
Dose-volume predictors of cardiac adverse events after high-dose thoracic radiation therapy for lung cancer: a systematic review and meta-analysisMédéa Locquet, Sophie Jacob, Xavier Geets, et al.
Pageof 20